Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious

Table 3 American College of Rheumatology core outcomes at 3 months

	Etanercept plus methotrexate	Etanercept only	P value
SJC	4.40 ± 0.57	5.56 ± 0.84	Not significant
TJC	4.78 ± 0.73	5.25 ± 0.90	Not significant
HAQ	1.20 ± 0.10	1.50 ± 0.12	Not significant
Patient global	28.0 ± 3.0	45.0 ± 4.0	< 0.001
Patient pain	27.6 ± 3.4	44.2 ± 4.7	< 0.005
Physician global	1.17 ± 0.09	1.55 ± 0.12	< 0.02
ESR	18.6 ± 1.8	22.6 ± 3.0	Not significant

Values presented as mean ± standard error of the mean. Comparisons are by unpaired Student t test. ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire disability index; patient global, patient assessment of global health by 100 mm visual analogue scale; patient pain, patient assessment of pain by 100 mm visual analogue scale; physician global, physician's assessment of global disease activity by five-point scale (0–4); SJC, swollen joint count (based on 28 joints); TJC, tender joint count (based on 28 joints).

ISSN: 1478-6362